1	A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482
2	in Healthy Adults for Prevention of Influenza A Illness (PENINSULA)
3	
4	Susanna K. Tan, ¹ Deborah Cebrik, ¹ David Plotnik, ¹ Maria L. Agostini, ¹ Keith Boundy, ¹ Christy
5	M. Hebner, ¹ Wendy W. Yeh, ¹ Phillip S. Pang, ¹ Jaynier Moya, ² Charles Fogarty, ³ Manuchehr
6	Darani, ⁴ Frederick G. Hayden ⁵
7	
8	¹ Vir Biotechnology, Inc., San Francisco, California, USA; ² Pines Care Research Center, Inc.,
9	Pembroke Pines, Florida, USA; ³ Spartanburg Medical Research, Spartanburg, South Carolina,
10	USA; ⁴ Marvel Clinical Research, Long Beach, California, USA; ⁵ University of Virginia School
11	of Medicine, Charlottesville, Virginia, USA
12	
13	Corresponding author:
14	Susanna K. Tan
15	Vir Biotechnology, Inc.
16	1800 Owens St
17	San Francisco, CA 94158 USA
18	Telephone: (415) 906-4324
19	Email: <u>stan@vir.bio</u>
20	

21 Key points

- 22 Prophylactic administration of 1200 mg of VIR-2482, an engineered human monoclonal
- antibody targeting a highly conserved epitope on the stem region of influenza A hemagglutinin,
- 24 did not significantly reduce risk of influenza-like illness from influenza A virus in healthy adults.

26 Abstract

27	Background: Influenza A results in significant morbidity and mortality. VIR-2482, an			
28	engineered human monoclonal antibody with extended half-life, targets a highly conserved			
29	epitope on the stem region of influenza A hemagglutinin, and may protect against seasonal and			
30	pandemic influenza.			
31	Methods: This double-blind, randomized, placebo-controlled, phase 2 study examined the safety			
32	and efficacy of VIR-2482 for seasonal influenza A illness prevention in unvaccinated healthy			
33	adults. Participants (N = 2977) were randomized 1:1:1 to receive VIR-2482 450 mg, VIR-2482			
34	1200 mg, or placebo via intramuscular (IM) injection. Primary and secondary efficacy endpoints			
35	were the proportions of participants with reverse transcriptase-polymerase chain reaction (RT-			
36	PCR)-confirmed influenza A infection and either protocol-defined influenza-like illness (ILI)			
37	and Centers for Disease Control and Prevention (CDC)-defined ILI or World Health			
38	Organization (WHO)-defined ILI, respectively.			
39	Results: VIR-2482 450 mg and 1200 mg prophylaxis did not reduce the risk of protocol-defined			
40	ILI with RT-PCR-confirmed influenza A versus placebo (relative risk reduction [RRR], 3.8%			
41	[95% CI: -67.3, 44.6] and 15.9% [95% CI: -49.3, 52.3], respectively). At the 1200 mg dose, the			
42	RRRs in influenza A illness were 57.2% [95% CI: -2.5, 82.2] using CDC-ILI and 44.1% [95%			
43	CI: -50.5, 79.3] using WHO-ILI definitions, respectively. Serum VIR-2482 levels were similar			
44	regardless of influenza status; variants with reduced VIR-2482 susceptibility were not detected.			
45	Local injection-site reactions were mild and similar across groups.			
46	Conclusion: VIR-2482 1200 mg IM was well tolerated but did not significantly prevent			
47	protocol-defined ILI. Secondary endpoint analyses suggest this dose may have reduced influenza			
48	A illness.			

- 49 Keywords: Influenza A; monoclonal antibody; VIR-2482
- 50 **Trial registration:** ClinicalTrials.gov identifier, NCT05567783

52 Introduction

According to the World Health Organization (WHO) approximately 1 billion annual cases of 53 seasonal influenza occur globally. Of these, an estimated 3 to 5 million cases are severe, with up 54 to 650,000 deaths per year [1]. Influenza A and B are both responsible for seasonal epidemics, 55 but influenza A infections account for the majority of hospitalizations and are the only influenza 56 type to cause pandemics [2]. Some patient groups are at high risk of influenza-associated 57 hospitalizations and mortality, including the elderly, immunocompromised hosts, and those with 58 59 certain comorbidities [3-5]. 60 Currently available seasonal influenza vaccines are influenza strain-specific, incompletely protective due to strain mismatch, and often inadequately immunogenic, especially 61 in high-risk groups like the elderly and immunocompromised [6]. Specifically, vaccine 62 effectiveness against medically attended influenza illness ranged from 19% to 60% in the United 63 64 States between the 2009 to 2023 influenza seasons [7]. Therefore, we hypothesized that an immunoprophylactic antibody with long half-life and activity against a broad range of influenza 65 A viruses could provide greater protection and obviate the need for updates to match the 66 prevalent circulating strains, especially in individuals at high-risk of complications. Additionally, 67 such a neutralizing antibody could facilitate a rapid response to an influenza A pandemic [8]. 68 69 VIR-2482 is a neutralizing, engineered human immunoglobulin G (IgG) monoclonal antibody (mAb) that targets a highly conserved epitope on the stem region of the influenza A 70 hemagglutinin (HA) protein [9, 10]. Epidemiologically, HA-stem binding antibodies have been 71 shown to correlate with protection from illness [11] and are the focus of ongoing efforts to create 72 universal influenza vaccines [8, 12]. 73

74	VIR-2482 and its parent mAb bind to HAs representing all 18 influenza A subtypes and
75	neutralize a broad panel of H1N1 and H3N2 influenza viruses spanning >100 years of antigenic
76	evolution. Administration of VIR-2482 reduced morbidity and mortality from infection by
77	seasonal and zoonotic strains of influenza in mice, ferrets, and macaques [9, 13-15]. VIR-2482 is
78	engineered to include an Fc LS mutation (M428L/N434S) that extends the elimination half-life
79	$(T_{1/2})$ through increased FcRn-mediated antibody recirculation [9].
80	In a phase 1 study in healthy volunteers (ClinicalTrials.gov Identifier: NCT04033406),
81	VIR-2482 doses of 60 to 1800 mg via intramuscular (IM) injection showed favorable local and
82	systemic tolerability, with few injection-site reactions [10]. Median time to maximum plasma
83	concentration of VIR-2482 ranged from 7.0 to 12.5 days, and median plasma $T_{1/2}\xspace$ was 57.1 to
84	70.6 days across dosing cohorts, indicating the potential for administration once per influenza
85	season.

We undertook this proof-of-concept, phase 2 trial to evaluate the safety, tolerability, and efficacy of VIR-2482 in preventing influenza A illness in healthy adults who had not received a seasonal influenza vaccine. Since vaccination was prohibited, participants were required to be at low risk of developing serious influenza-related complications.

90

91 METHODS

92 Study Design

This was a double-blind, randomized, placebo-controlled, dose-ranging study conducted at 53
centers in the United States during the 2022 to 2023 Northern Hemisphere influenza season. The
study was conducted in accordance with the principles of the Declaration of Helsinki and the

study protocol was approved by the relevant institutional ethics committees (authorizing body:

97 WCG Institutional Review Board). All participants provided written informed consent.

98

99 **Participants**

Males and nonpregnant/nonlactating females aged 18 to <65 years were eligible to participate if 100 they were in good health as determined from medical history. Key inclusion criteria included 101 body mass index (BMI) 18.0 to 35.0 kg/m² and no clinically significant findings from physical 102 examination, 12-lead electrocardiogram, and laboratory values. Participants were excluded if 103 they had prior or planned receipt of any influenza vaccine for the upcoming season, history or 104 105 clinical evidence of conditions considered high risk for developing influenza-related 106 complications, or confirmed influenza infection within 3 months of randomization (see 107 Supplementary Methods).

108

109 Antibody Administration and Safety Monitoring

VIR-2482 or saline placebo was administered as 2 separate 4-mL IM injections. Participants
were randomized 1:1:1 to VIR-2482 450 mg (1 dose of VIR-2482 and 1 dose of placebo), VIR2482 1200 mg (2 doses of VIR-2482) or placebo (2 doses of placebo) on Day 1. These doses
were selected based on the acceptable safety and tolerability of VIR-2482 doses in the phase 1
study and target serum concentrations estimated from in vitro neutralization data [10]. VIR-2482
was administered as a 150-mg/mL solution. The preferred injection site was the thigh, with the
buttock as an alternative.

117	Participants remained at the clinical study site for ≥ 2 hours postdose to assess safety,
118	including solicited local tolerability at the injection sites performed at 1-hour postdose.
119	Following discharge, participants completed an electronic diary card from Days 1 to 7 to record
120	injection site and systemic reactions and body temperature. Follow-up visits were conducted at 1,
121	4, and 12 weeks postdosing and at the end of the influenza season (EOIS).
122	Adverse events (AEs) were recorded through the end of the study, with severity assessed
123	according to the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled
124	in Preventative Vaccine Clinical Trials [16]. Immunogenicity of VIR-2482 was evaluated
125	according to incidence and titers of antidrug antibodies (ADAs) using validated methods [10].
126	
127	Illness Surveillance
128	Participants completed an electronic diary for influenza-like illness (ILI) symptoms twice per
129	week from Day 1 through EOIS (April 16, 2023). Signs and symptoms included sore throat,
130	cough, sputum production, wheezing, difficulty breathing, temperature >37.8°C, chills,
131	weakness, or myalgia. Participants experiencing any ILI symptoms were requested to visit the
132	study center within 3 days of symptom onset for nasopharyngeal swab (NPS) collection.
133	Influenza A was confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR) using a
134	sponsor-provided point-of-care device (Xpert-Xpress CoV-2/RSV/Flu plus; Cepheid; Sunnyvale,
135	CA) or a central virology laboratory assay (Respiratory Panel 1; Seegene; Seoul, South Korea)
136	performed at DDL Diagnostic Laboratories (Rijswijk, Netherlands). Participants with ILI were
137	managed according to local standard of care, and symptoms were followed-up daily via

documented using the Influenza Intensity and Impact Questionnaire Flu-iiQ[™] [17] administered
from Day 1 of symptom onset through Day 10.

141

142 **Pharmacokinetics**

Serum samples for pharmacokinetics (PK) and immunogenicity analyses were collected predose and at the follow-up visits. NPS for PK analysis [10] were collected from all participants at the EOIS visit and at Weeks 1, 4, and 12 from a subset of participants in an optional PK substudy. In participants with ILI, additional samples for PK, ADA, and virologic analyses were collected at the ILI confirmation clinic visit.

148

149 Outcomes

The primary efficacy endpoint was the proportion of participants with RT-PCR positivity for 150 influenza A and protocol-defined ILI. The protocol definition required ≥ 1 respiratory symptom 151 152 (sore throat, cough, sputum production, wheezing, or difficulty breathing) and ≥ 1 systemic sign 153 or symptom (temperature >37.8°C, chills, weakness, or myalgia). Prespecified secondary efficacy endpoints were the proportions of participants with RT-PCR-confirmed influenza A and 154 ILI as defined by the Centers for Disease Control and Prevention (CDC; temperature >37.8°C 155 with sore throat or cough and RT-PCR confirmation) and WHO (temperature >38°C with cough 156 157 and RT-PCR confirmation).

Exploratory endpoints included the severity and duration, as the time of onset of first
 symptom through when all respiratory symptoms were resolved for ≥24 hours, of participant reported ILI signs and symptoms with the Flu-iiQTM instrument [17]. Virologic analyses on NPS

161	samples determined the proportion of participants with RT-PCR-confirmed influenza A by virus		
162	subtype and assessed emergence of virus variants with reduced susceptibility to VIR-2482. Next-		
163	generation sequencing of the influenza A HA gene was performed at DDL Diagnostic		
164	Laboratories (Rijswijk, Netherlands). Virus successfully cultured in MDCK cells was assessed		
165	for reduced susceptibility using an in vitro neutralization assay at Viroclinics Biosciences		
166	(Rotterdam, Netherlands) [18]. Sequence and phenotypic results were compared with respective		
167	subtype vaccine reference strains (H1N1: A/Victoria/2750/2019; H3N2: A/Darwin/9/2021 and		
168	A/Darwin/6/2021, respectively).		
169			
170	Statistical Analysis		
171	A sample size of approximately 3000 participants was needed to provide approximately 80%		

power to detect VIR-2482 efficacy (a true relative risk reduction [RRR] of 70%) of 1 VIR-2482
dose level compared with placebo, assuming an attack rate of ≥2.25% in the placebo group [19,
20]. Efficacy and safety were analyzed in all randomized participants receiving any amount of
study drug or placebo. Efficacy was assessed based on the study intervention to which
participants were randomly assigned, and safety was assessed based on the intervention received.
Details on primary and secondary estimands and statistical analyses are provided in the
Supplementary Methods.

A modified Poisson regression with robust variance was used as the efficacy analysis model to estimate the relative risk of the incidence of protocol-/CDC-/WHO-defined ILI with RT-PCR–confirmed influenza A in each VIR-2482 group compared with the placebo group, with treatment group as the only factor in each model. A hierarchical fixed sequence testing procedure

- 183 was used to control the overall type I error as outlined in the Supplementary Methods. Formal
- 184 comparisons precluded by the hierarchical testing strategy were considered descriptive.

185

186 **Results**

- 187 *Participants and Disposition*
- 188 Between October 13, 2022, and January 6, 2023, participants (N = 2977) were randomized, and
- 189 2956 (99.3%) received study intervention (**Figure 1**). Across treatment groups, mean age was
- 190 39.5 years and 54% were female (**Table 1**). Study drug or placebo was administered in the thigh
- in approximately 78% of participants. Through the end of study, discontinuation rates were <5%
- and comparable across treatment groups.

193

194 *Efficacy Outcomes*

- 195 The primary endpoint of protocol-defined ILI with RT-PCR confirmed influenza A was observed
- in similar numbers of participants across groups (**Table 2**). A nonsignificant RRR of 15.9%
- 197 (95% CI: -49.3, 52.6) comparing VIR-2482 1200 mg versus placebo was observed. Predefined
- subgroup analyses between these 2 groups showed RRRs consistent with that of the overall
- 199 population (Supplementary Figure 1). In the VIR-2482 1200 mg group, RRRs versus placebo
- 200 for CDC- and WHO-defined ILI with RT-PCR-confirmed influenza A were 57.2% (95% CI: -
- 201 2.5, 82.2) and 44.1% (95% CI: -50.5, 79.3), respectively (**Table 2**).

To investigate the impact of pre-existing infections or infections that may have been acquired prior to VIR-2482 achieving adequate tissue distribution, we conducted posthoc

204	analyses excluding 10 cases of protocol-defined ILI, 5 cases of CDC-defined ILI, and 4 cases of
205	WHO-defined ILI that occurred within 7 days following study drug administration. Numerically
206	higher RRRs of ILI were observed in the VIR-2482 1200 mg group (protocol-defined: 34.0%
207	[95% CI: -25.7, 65.3]; CDC-defined: 64.9% [95% CI: 3.9, 87.2]; WHO-defined: 42.9% [95% CI:
208	-69.7, 80.8]; Supplementary Table 1).
209	Most participants with protocol-defined II I reported moderate to severe symptoms
200	
210	Symptom severity of ILI measured by FluiiQ TM was similar across groups (Supplemental Table
211	2). Participants who received VIR-2482 1200 mg had a numerically shorter time to resolution of
212	protocol-defined ILI than participants who received placebo (median: 85.8 h [interquartile range
212	
213	(IQR): 57.7-137.2] vs 111.9 h [IQR: 72.1-130.4]). No influenza-related hospitalizations or deaths

215

216 *Safety*

Treatment-emergent AEs (TEAEs) were reported in 62% to 65% of participants across study groups (**Table 3**). The most frequently reported TEAEs (>5% of participants in any group) were upper respiratory tract infection, COVID-19, oropharyngeal pain, cough, viral infection, and myalgia. Treatment-related TEAEs were reported in $\leq 2\%$ of participants and were similarly distributed across groups. Serious TEAEs were uncommon ($\leq 1\%$ across groups), and none were considered related to study treatment. Five deaths occurred during the study, and none were considered related to treatment.

Incidences of solicited injection-site reactions at 1-hour postdose were <10% in all 3
 groups (Supplementary Table 3). Grade 1 (mild) injection-site pain was the most common self-

226	reported injection-site reaction (placebo, 5.6%; VIR-2482 450 mg, 6.1%; VIR-2482 1200 mg,
227	8.4%) during the on-site assessment. Mild injection-site pain was also the most common
228	injection-site reaction reported on the electronic diary card during Days 1 to 7 (placebo, 22.6%;
229	VIR-2482 450 mg, 24.5%; VIR-2482 1200 mg, 23.9%; Supplementary Table 4). The most
230	common participant-reported systemic reactions included mild myalgia (12.3%-14.9%), mild
231	headache (12.5%-14.0%), and mild malaise (9.8%-10.3%; Supplementary Table 5). No
232	treatment-emergent anaphylaxis events were reported. Incidences of treatment-emergent clinical
233	laboratory and vital signs abnormalities were similar across groups.
234	
235	Virologic Analyses
236	Among participants with protocol-defined ILI with RT-PCR-confirmed influenza A, H3 subtype
237	virus was detected in 56% to 72% and H1 subtype in 16% to 36% of illnesses across study
238	groups; 8% to 19.1% of illnesses had an unknown influenza A subtype (Supplementary Table
239	6).
240	Sequence and phenotypic data availability are described in Supplementary Table 7 .
241	Influenza A virus isolates, including the small number where a VIR-2482 epitope amino acid
242	substitution was detected by sequence analysis, retained susceptibility to VIR-2482 with fold
243	changes in half maximal effective concentration (EC ₅₀) ranging from 0.23 to 2.55 compared with
244	the respective subtype vaccine reference strain in vitro.

245

246 *Pharmacokinetics*

247	Following VIR-2482 1200 mg, median serum T_{max} was 6.95 days, geometric mean serum C_{max}
248	was 111 μ g/mL (CV% = 52.1%), and geometric mean serum concentration at EOIS was 18.5
249	μ g/mL (CV% = 98.8). Median T _{1/2} was 54.7 to 55.4 days across VIR-2482 doses. Compared
250	with gluteal administration, thigh injection resulted in 79.9% higher C_{max} and 43.8% higher area
251	under the curve (AUC) for the 450 mg dose and 97.5% higher C_{max} and 55.6% higher AUC for
252	the 1200 mg dose (Supplementary Table 8).
253	Serum and NPS concentration-time data through 180 days postdose are displayed in
254	Figure 2 and NPS:serum ratios are displayed in Supplemental Figure S2. The NPS
255	concentrations of VIR-2482 averaged 2.1% to 7.8% of within-subject serum concentrations
256	across doses and time points. VIR-2482 recipients who experienced breakthrough influenza A
257	illness had serum levels that were comparable to those who did not (Supplemental Table 9).

258

259 *Immunogenicity*

The incidence of ADA was 5.4% (53/980) in the 450 mg group and 5.1% (51/992) in the 1200 mg group. A >4-fold increase in ADA titer relative to baseline was observed in 1 participant receiving VIR-2482 1200 mg, while the titer of all other pre-existing ADAs was unaffected by treatment. Further, ADAs were not correlated with AEs, injection-site reactions, or aberrant PK in any participant (data not shown).

265

266 Discussion

Neutralizing mAbs have demonstrated the ability to prevent symptomatic respiratory diseases,
such as COVID-19 in adults [21] and respiratory syncytial virus (RSV) in infants [22]. Broadly

269	neutralizing HA-stem binding antibodies are recognized as potential pandemic influenza		
270	countermeasures [13, 23], and studies of such antibodies have shown therapeutic efficacy in		
271	experimentally induced human influenza infections [24, 25] but have demonstrated inconsistent		
272	efficacy in treating uncomplicated seasonal influenza [26-28]. The current trial found that		
273	prophylactic IM VIR-2482 administration was generally well tolerated, but did not significantly		
274	protect against protocol-defined ILI with RT-PCR-confirmed influenza A compared with		
275	placebo. Several explanations could account for the lack of significant clinical efficacy observed		
276	in this study.		

Two potential contributory factors were the early onset of influenza activity in the 2022 277 to 2023 influenza season [29] that coincided with study enrollment and dosing and the known lag 278 279 between maximal serum and tissue concentrations following IM dosing. When RT-PCRconfirmed illnesses that occurred <7 days after dosing were excluded, posthoc analyses showed 280 greater reductions in ILI in VIR-2482 1200 mg recipients, including 65% RRR of the CDC-281 defined ILI cases in the 1200 mg group compared with placebo. These results suggest that early 282 283 ILIs could have been due to either incubating infections prior to VIR-2482 dosing or infections 284 acquired during the window prior to adequate tissue distribution. In addition, we noted that participants who received VIR-2482 1200 mg had a numerically shorter time to resolution of 285 protocol-defined ILI than participants who received placebo, suggesting clinical activity at this 286 287 dose.

The apparent dose-response observed in those who received VIR-2482 1200 mg versus 450 mg suggests the possibility that the onset and durability of protection was potentially limited by the drug levels achieved in relevant tissue compartments. The VIR-2482 1200 mg dose selection was based on modelling using in vitro EC₉₀ data that estimated it would provide

antiviral activity for >8 months [10]. Additional PK-pharmacodynamics analyses are needed to
better understand the tissue distribution of VIR-2482 and the optimal drug levels needed in the
respiratory tract.

The serum and nasopharyngeal exposures of VIR-2482 observed in this study were comparable to those reported in the phase 1 study of healthy volunteers [10]. Also, the overall incidence of ADAs was low and not correlated with reduced serum concentrations or incidence of infections. Consequently, dosing errors, manufacturing concerns, or aberrant PK are unlikely explanations for trial failure. Viral resistance was also unlikely to explain the lack of efficacy, since viruses cultured from participants with influenza A infections retained susceptibility to VIR-2482 compared with respective subtype reference viruses in vitro.

One hypothesis that may account for these results is that the antiviral activities of HAstem antibodies observed in vitro or in in vivo animal models do not translate into clinically meaningful benefit when administered to unvaccinated healthy adults for prophylaxis of symptomatic infection. The HA-stem antibodies that block fusion of the endocytosed virion within cells may not be as effective at preventing symptomatic infection compared with the head-binding HA antibodies typically induced by seasonal vaccines that block receptor binding.

An additional hypothesis is that VIR-2482 has clinically meaningful activity, but the selected endpoints, dose, study population, or timing did not enable a positive trial result. Unvaccinated healthy adults were selected as the trial population in this study to better understand the tolerability profile and clinical activity of VIR-2482 without prior vaccination. The prespecified CDC-defined secondary endpoint, which requires a temperature >37.8°C, demonstrated numerically a 57.2% RRR in symptomatic RT-PCR–confirmed infection in VIR-2482 1200 mg recipients versus the 15.9% RRR observed for the primary endpoint. This raises

315	the possibility that VIR-2482 could be more effective in preventing severe or systemic influenza
316	illness in a more vulnerable patient population than unvaccinated healthy adults. Indeed, this
317	concept has been demonstrated with mAbs targeting RSV in infants, where the primary endpoint
318	is not mild symptomatic illness, but medically attended lower respiratory tract infection [22].
319	COVID-19 vaccines and mAbs have also demonstrated effectiveness against severe disease but
320	are less effective in protecting against mild illness [30-32].
321	In conclusion, although VIR-2482 was well tolerated, it did not significantly prevent
322	influenza A illness in healthy unimmunized adults at IM doses up to 1200 mg. There remains a
323	clinical need for long-duration prophylactic interventions that provide protection against the
324	morbidity and mortality of influenza in individuals at high-risk of complications. The findings
325	from this trial provide valuable insights to support the future development of broad spectrum
326	mAbs for the prevention of influenza illness.

327

328 Funding

329 This work was supported by Vir Biotechnology, Inc. and with federal funds from the Department

of Health and Human Services (HHS); Administration for Strategic Preparedness and Response

331 (ASPR); and Biomedical Advanced Research and Development Authority (BARDA) under

contract number 75A50122C00081. The findings and conclusions herein are those of the authors

and do not necessarily represent the views of the HHS or its components.

334

335 Acknowledgements

336	The authors thank all study participants, investigators, site personnel, and operational staff. The
337	authors also thank Jeanne McKeon, PhD, of Lumanity Scientific Inc., for medical writing and
338	editorial support, which was funded by Vir Biotechnology, Inc.

339

340 Author Contributions

341 Susanna K. Tan, Deborah Cebrik, David Plotnik, Maria L. Agostini, Keith Boundy, Christy M.

Hebner, Wendy W. Yeh, Philip S. Pang, and Frederick G. Hayden conceptualized and designed

the study. Jaynier Moya, Charles Fogarty, and Manuchehr Darani acquired and analyzed data.

344 Deborah Cebrik conducted the statistical analyses. All authors interpreted data, drafted the

345 manuscript, and critically reviewed and revised the manuscript for important intellectual content.

346 All authors had full access to all the data in the study, take responsibility for the accuracy of the

analysis, and had authority over manuscript preparation and the decision to submit the

348 manuscript for publication.

349

350 **Conflict of Interest Disclosures**

351 Susanna K. Tan, Deborah Cebrik, David Plotnik, Maria L. Agostini, Keith Boundy, Wendy W.

352 Yeh, and Philip S. Pang are employees of Vir Biotechnology, Inc and report stock ownership in

353 Vir Biotechnology, Inc. Christy M. Hebner is a former employee and shareholder of Vir

Biotechnology, Inc. and is a coauthor on select Vir Biotechnology, Inc. patents. Jaynier Moya

and Manuchehr Darani have nothing to disclose. Charles Fogarty reports receiving grant support

from Vir Biotechnology, Inc. for conduct of the clinical trial. Frederick G. Hayden has served as

a nonpaid consultant to Vir Biotechnology, Inc. and other companies involved in developing

- 358 influenza therapeutics or vaccines, including Appili, Arcturus, Gilead, GSK, Janssen/JNJ,
- 359 MedImmune, Medivector/Fujifilm, Merck, Ridgeback, Roche/Genentech, and Visterra. Cidara,
- 360 Enanta, Shionogi, and Versatope have made charitable donations for Dr. Hayden's consulting
- time, and both Shionogi and Roche have provided meeting travel support.

362

363 Data Sharing Statement

Relevant data can be found within the manuscript and supplemental data.

366 REFERENCES

367	1.	World Health Organization. Influenza (seasonal) key facts. Available at:	

- 368 <u>https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)</u>. Accessed 25
- 369 October 2023.
- 2. Wright P, Neumann G, Kawaoka Y. Orthomyxoviruses. In: Fields B, Knipe D, Howley
- P. Fields Virology. 5th ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams
- **372** & Wilkins, **2007**: 1691-1740.
- 373 3. GBD 2017 Influenza Collaborators. Mortality, morbidity, and hospitalisations due to
- influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of
- 375 Disease Study 2017. Lancet Respir Med, **2019**; 7: 69-89.
- 4. Mertz D, Kim TH, Johnstone J, et al. Populations at risk for severe or complicated
- influenza illness: systematic review and meta-analysis. BMJ, **2013**; 347: f5061.
- 5. Collins JP, Campbell AP, Openo K, et al. Outcomes of immunocompromised adults with
- laboratory-confirmed influenza in the United States, 2011–2015. Clin Infect Dis, **2020**;
- **380** 70: 2121-30.
- 381 6. Becker T, Elbahesh H, Reperant LA, Rimmelzwaan GF, Osterhaus A. Influenza
- vaccines: successes and continuing challenges. J Infect Dis, **2021**; 224: S405-S19.
- 383 7. Centers for Disease Control and Prevention. CDC seasonal flu vaccine effectiveness
- 384 studies. Available at: <u>https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm</u>.
- 385 Accessed 25 October 2023.
- Wang WC, Sayedahmed EE, Sambhara S, Mittal SK. Progress towards the Development
 of a Universal Influenza Vaccine. Viruses, 2022; 14: 1684.

J_{1} J_{1} J_{2} J_{1} J_{2} J_{1} J_{2} J_{1} J_{2} J_{2} J_{1} J_{2} J_{2} J_{1} J_{2} J_{2} J_{1} J_{2} J_{2	388
--	-----

- antibody for the prophylaxis of influenza A illness. Presented at: IDWeek; 21-25 October
 2020; Virtual. Poster #902873.
- 10. Plotnik D, Sager JE, Aryal M, et al. A phase 1 study in healthy volunteers to investigate
- the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the
- 393 prevention of severe influenza A illness. Antimicrob Agents Chemother, **2024**;
- e0127323.
- 11. Ng S, Nachbagauer R, Balmaseda A, et al. Novel correlates of protection against

pandemic H1N1 influenza A virus infection. Nat Med, **2019**; 25: 962-967.

- 12. De Jong NMC, Aartse A, Van Gils MJ, Eggink D. Development of broadly reactive
- influenza vaccines by targeting the conserved regions of the hemagglutinin stem and head
 domains. Expert Rev Vaccines, 2020; 19: 563-77.
- 400 13. Paules CI, Lakdawala S, McAuliffe JM, et al. The hemagglutinin A stem antibody
- 401 MEDI8852 prevents and controls disease and limits transmission of pandemic influenza
 402 viruses. J Infect Dis, 2017; 216: 356-65.
- 403 14. Kallewaard NL, Corti D, Collins PJ, et al. Structure and function analysis of an antibody
 404 recognizing all influenza A subtypes. Cell, **2016**; 166: 596-608.
- 405 15. Gillespie R, Cooper K, Guerra Canedo V, et al. Pre-exposure antibody prophylaxis
- 406 protects non-human primates from severe influenza disease. Presented at: Ninth
- 407 European Scientific Working Group on Influenza (ESWI) Influenza Conference; 17-20
- 408 September 2023; Valencia, Spain. Poster #725.

409	16.	Food and Drug Administration (FDA). Toxicity grading scale for healthy adult and
410		adolescent volunteers enrolled in preventative vaccine clinical trials. Available at:

https://www.fda.gov/media/73679/download. Accessed 16 September 2022.

- 17. Osborne RH, Norquist JM, Elsworth GR, et al. Development and validation of the 412
- Influenza Intensity and Impact Questionnaire (FluiiQTM). Value Health, 2011; 14: 687-413
- 699. 414

- van Baalen CA, Jeeninga RE, Penders GH, et al. ViroSpot microneutralization assay for 18. 415 antigenic characterization of human influenza viruses. Vaccine, 2017; 35: 46-52. 416
- 417 19. Jayasundara K, Soobiah C, Thommes E, Tricco AC, Chit A. Natural attack rate of
- influenza in unvaccinated children and adults: a meta-regression analysis. BMC Infect 418 Dis, 2014; 14: 670.
- 419
- Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of 420 20.
- influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis, 2012; 12: 421 422 36-44.
- 21. Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab-423
- cilgavimab) for prevention of Covid-19. N Engl J Med, 2022; 386: 2188-200. 424
- 425 22. Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy latepreterm and term infants. N Engl J Med, 2022; 386: 837-846. 426
- 427 23. Gostic KM, Ambrose M, Worobey M, Lloyd-Smith JO. Potent protection against H5N1 428 and H7N9 influenza via childhood hemagglutinin imprinting. Science, 2016; 354: 722-
- 726. 429

430	24.	McBride JM.	Lim JJ.	Burgess 7	T. et al.	Phase 2	2 randomized	trial of	of the safety	v and efficacy
										/

- 431 of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza A
- 432 virus challenge model. Antimicrob Agents Chemother, **2017**; 61: e01154-17.
- 433 25. Sloan SE, Szretter KJ, Sundaresh B, et al. Clinical and virological responses to a broad-
- 434 spectrum human monoclonal antibody in an influenza virus challenge study. Antiviral
- 435 Res, **2020**; 184: 104763.
- 436 26. Lim JJ, Dar S, Venter D, et al. A phase 2 randomized, double-blind, placebo-controlled
- 437 trial of the monoclonal antibody MHAA4549A in patients with acute uncomplicated

438 influenza A infection. Open Forum Infect Dis, **2022**; 9: ofab630.

- 439 27. Ali SO, Takas T, Nyborg A, et al. Evaluation of MEDI8852, an anti-influenza A
- 440 monoclonal antibody, in treating acute uncomplicated influenza. Antimicrob Agents
 441 Chemother, 2018; 62: e00694-18.
- 442 28. Hershberger E, Sloan S, Narayan K, et al. Safety and efficacy of monoclonal antibody
- 443 VIS410 in adults with uncomplicated influenza A infection: results from a randomized,
- 444 double-blind, phase-2, placebo-controlled study. EBioMedicine, **2019**; 40: 574-582.
- 445 29. Centers for Disease Control and Prevention. Influenza activity in the United States during
- the 2022-23 season and composition of the 2023-24 influenza vaccine. Available at:
- 447 https://www.cdc.gov/flu/spotlights/2023-2024/22-23-summary-technical-report.htm.
- 448 Accessed 26 October 2023.
- 30. Bar-On YM, Goldberg Y, Mandel M, et al. Protection against Covid-19 by BNT162b2
 booster across age groups. N Engl J Med, 2021; 385: 2421-2430.
- 451 31. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of previous infection and
- 452 vaccination on symptomatic Omicron infections. N Engl J Med, **2022**; 387: 21-34.

- 453 32. Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-
- 454 CoV-2 Omicron and Delta variants. Nat Med, **2022**; 28: 1063-1071.

455

457 TABLES AND FIGURES

458 Table 1. Baseline Characteristics (Full Analysis Set)

	Placebo (n =	VIR-2482 450	VIR-2482	Total
	983)	mg (n = 981)	1200 mg (n =	(N = 2956)
			992)	
Age at randomization, ye	ars			L
Mean (SD)	39.7 (12.3)	39.2 (12.5)	39.6 (11.7)	39.5 (12.2)
Median (range)	39.0 (18-64)	38.0 (18-64)	39.0 (18-64)	39.0 (18-64)
Sex, no. (%)				
Male	453 (46.1)	436 (44.4)	469 (47.3)	1358 (45.9)
Female	530 (53.9)	545 (55.6)	523 (52.7)	1598 (54.1)
Race, no. (%)				
American Indian or	7 (0.7)	7 (0.7)	7 (0.7)	21 (0.7)
Alaskan native				
Asian	26 (2.6)	26 (2.7)	29 (2.9)	81 (2.7)
Black or African	166 (16.9)	154 (15.7)	176 (17.7)	496 (16.8)
American				

Native Hawaiian or	4 (0.4)	5 (0.5)	4 (0.4)	13 (0.4)
other Pacific Islander				
White	758 (77.1)	752 (76.7)	747 (75.3)	2257 (76.4)
Multiracial	6 (0.6)	17 (1.7)	11 (1.1)	34 (1.2)
Not	16 (1.6)	20 (2.0)	18 (1.8)	54 (1.8)
reported/unknown				
Ethnicity, no. (%)	· · · · · · · · · · · · · · · · · · ·		I	I
Hispanic or Latino	357 (36.3)	370 (37.7)	370 (37.3)	1097 (37.1)
Not Hispanic or	620 (63.1)	607 (61.9)	621 (62.6)	1848 (62.5)
Latino				
Not	6 (0.6)	4 (0.4)	1 (0.1)	11 (0.4)
reported/unknown				
Body mass index, kg/m ²				
Mean (SD)	27.2 (4.1)	27.3 (4.1)	27.4 (4.2)	27.3 (4.1)
Median (range)	27.2 (18.0-35.0)	27.5 (18.0-	27.7 (18.0-	27.5 (18.0-
		36.6)	35.1)	36.6)
Injection site location, no	. (%)		1	1
Thigh	762 (77.5)	757 (77.2)	783 (78.9)	2302 (77.9)

Buttock	219 (22.3)	223 (22.7)	207 (20.9)	649 (22.0)

459

461 Table 2. Occurrence of Influenza-Like Illness With RT-PCR Confirmed Influenza A

462 Through End of Influenza Season (Full Analysis Set)

	Placebo	VIR-2482 450 mg	VIR-2482 1200
	(n = 983)	(n = 981)	mg (n = 992)
Primary endpoint			
No. (%) participants with	25 (2.54)	24 (2.45)	21 (2.12)
protocol-defined ILI ^a			
Relative risk reduction vs	-	3.78	15.85
placebo, %			
95% CI (%) ^b	-	-67.23, 44.63	-49.27, 52.56
P-value	-	-	0.56
Secondary endpoints			
No. (%) participants with	17 (1.73)	15 (1.53)	7 (0.71)
CDC-defined ILI ^a			
Relative risk reduction vs	-	11.45	57.23
placebo, %			
95% CI (%) ^b	-	-76.25, 55.51	-2.51, 82.15
No. (%) participants with	11 (1.12)	12 (1.22)	6 (0.6)
WHO-defined ILI ^a			
Relative risk reduction vs	-	-9.80	44.13
placebo, %			
95% CI (%) ^b	-	-147.41, 51.27	-50.49, 79.26

- 463 CDC, Centers for Disease Control and Prevention; ILI, influenza-like illness; RT-PCR, reverse
- 464 transcriptase-polymerase chain reaction; WHO, World Health Organization.
- ^aParticipants with multiple occurrences of protocol-, CDC-, or WHO-defined illness with RT-
- 466 PCR–confirmed influenza A were counted once.
- ^bThe 95% CI for the primary endpoint analysis of 450 mg versus placebo and for analyses of
- 468 secondary endpoints are nominal, and not adjusted for multiplicity.

469 Table 3. Occurrences of TEAEs Through the End of the Study (Safety Set)

	Placebo	VIR-2482 450 mg	VIR-2482 1200
	(n = 983)	(n = 981)	mg (n = 992)
	n (%)	n (%)	n (%)
Any TEAE	639 (65.0)	636 (64.8)	613 (61.8)
TEAEs by maximum toxicity	grade	I	
Grade 1	441 (44.9)	449 (45.8)	406 (40.9)
Grade 2	181 (18.4)	174 (17.7)	190 (19.2)
Grade 3	14 (1.4)	10 (1.0)	12 (1.2)
Grade 4	3 (0.3)	3 (0.3)	5 (0.5)
Study treatment-related	15 (1.5)	20 (2.0)	17 (1.7)
TEAEs			
TEAEs leading to study	0	0	0
treatment discontinuation or			
interruption			
Serious TEAEs	9 (0.9)	10 (1.0)	13 (1.3)
Study treatment-related	0	0	0
serious TEAEs			
TEAEs leading to death ^a	0	2 (0.2)	3 (0.3)
TEAEs occurring in >5% of p	participants in any tre	atment group	
Upper respiratory tract	248 (25.2)	243 (24.8)	245 (24.7)
infection			
COVID-19	106 (10.8)	93 (9.5)	92 (9.3)

Oropharyngeal pain	75 (7.6)	95 (9.7)	87 (8.8)
Cough	72 (7.3)	88 (9.0)	84 (8.5)
Viral infection	70 (7.1)	56 (5.7)	48 (4.8)
Myalgia	38 (3.9)	51 (5.2)	36 (3.6)

- 470 TEAE, treatment-emergent adverse event.
- 471 A participant with multiple occurrences of the same TEAE was counted only once at the

472 maximum toxicity grade or strongest relationship to study intervention.

⁴⁷³ ^aReasons for death were accidental drug overdose (nontreatment intervention) and suicide (both

474 VIR-2482 450 mg), cardiac arrhythmia, cardiorespiratory arrest, and intentional multidrug

475 overdose (nontreatment intervention; all VIR-2482 1200 mg). None of the deaths were

476 considered related to study treatment.

478 Figure 1. Participant Disposition



480 Based on efficacy findings, the study was terminated early and follow-up into the second influenza season did not take place.

481 Figure 2. Pharmacokinetic Profiles of VIR-2482 Following Intramuscular Administration of (A) 450-mg and (B) 1200 mg

482 **Doses**



⁴⁸⁴ NPS, nasopharyngeal swab.

485 Supplementary Methods

486 *Participant Exclusion Criteria*

487 Participants were excluded from this study if they had an established diagnosis of a condition
488 considered high risk for developing influenza-related complications. Such conditions are listed
489 below:

490	• Asthma.
491	• Neurologic and neurodevelopmental conditions (such as cerebral palsy, epilepsy
492	[seizure disorders], stroke, intellectual disability, moderate to severe developmental
493	delay, muscular dystrophy, or spinal cord injury).
494	• Chronic lung disease (such as chronic obstructive pulmonary disease, emphysema,
495	and cystic fibrosis).
496	• Heart disease (such as congenital heart disease, congestive heart failure, and coronary
497	artery disease).
498	• Blood disorders (such as sickle cell disease and thalassemia).
499	• Endocrine disorders (such as diabetes and adrenal insufficiency).
500	Chronic kidney disease.
501	• Chronic liver disease.
502	• Metabolic disorders (such as inherited metabolic disorders and mitochondrial
503	disorders).
504	• Weakened immune system due to disease or medication (such as individuals with
505	HIV or AIDS, or cancer, or those taking chronic steroids).
506	• People younger than 19 years of age who are receiving long-term aspirin therapy.

507

508 Statistical Analysis

The primary estimand was defined as the relative risk of VIR-2482 versus placebo of protocol-509 defined ILI with central virology laboratory or point-of-care RT-PCR-confirmed influenza A in 510 511 the absence of RT-PCR-confirmed coinfection with influenza B, respiratory syncytial virus, 512 and/or severe acute respiratory syndrome coronavirus-2 through EOIS in the full analysis set. 513 The treatment policy strategy was used for the handling of intercurrent events of receipt of any 514 nonstudy influenza antiviral and receipt of an authorized influenza vaccine. Participants who 515 died due to influenza A were to be considered to have met the primary endpoint. Participants 516 who died for reasons other than influenza A illness were handled using the while-alive approach, where data up until the time of death were included in the analysis. The secondary estimands 517 518 were defined similarly to the primary estimand, with all attributes being the same other than the endpoints (CDC- and WHO-defined ILI with central virology laboratory or point-of-care RT-519 520 PCR-confirmed influenza A in the absence of RT-PCR-confirmed coinfection with influenza B, respiratory syncytial virus, and/or severe acute respiratory syndrome coronavirus-2 through 521 522 EOIS).

VIR-2482 efficacy was calculated as the relative risk reduction in the occurrence of protocol-/CDC-/WHO-defined ILI with RT-PCR–confirmed influenza A in each VIR-2482 group compared with that in the placebo group, or $100\% \times (1 - \text{the relative risk})$, with the result expressed as a percentage, with corresponding 95% CI. Participants with multiple occurrences of protocol-/CDC-/WHO-defined ILI with RT-PCR–confirmed influenza A were counted once at the earliest occurrence. Missing endpoint data were imputed with the observed incidence of protocol-/CDC-/WHO-defined ILI with RT-PCR–confirmed influenza A in the placebo group by

- 530 means of multiple imputation. Exploratory analyses were conducted in predefined subgroups
- using the same methodology as the primary efficacy endpoint.

- 533 *Hierarchical Testing*
- For the primary estimand, the comparison of VIR-2482 450 mg versus placebo was tested only if
- the comparison of VIR-2482 1200 mg versus placebo was statistically significant at the 0.05
- level (2-sided). Statistical testing was to continue for each comparison for the secondary
- estimands only if the comparison of VIR-2482 450 mg versus placebo for the primary estimand
- 538 was tested and statistically significant at the 0.05 level (2-sided).

539 Supplementary Table 1. Posthoc: Participants With RT-PCR Confirmed Influenza A ILI Through EOIS, Excluding RT-PCR

540 Confirmed Influenza A ILI With Onset in the First 7 Days Following Study Intervention Administration (Full Analysis Set)

	Placebo (n = 983)	VIR-2482 450 mg (n =	VIR-2482 1200 mg (n =
		981)	992)
No. (%) participants with protocol-			
defined ILI with RT-PCR-confirmed	23 (2.3)	22 (2.2)	15 (1.5)
influenza A ^a			
Relative risk reduction (95% CI) for			
VIR-2482 vs placebo ^b		4.14 (-70.82, 46.21)	34.01 (-25.67, 65.34)
No. (%) participants with CDC-defined			
ILI with RT-PCR confirmed influenza A ^a	15 (1.53)	14 (1.43)	5 (0.50)
Relative risk reduction (95% CI) for			
VIR-2482 vs placebo ^b		6.52 (-92.60, 54.63)	64.88 (3.87, 87.17)
No. (%) participants with WHO-defined	0 (0 00)	11 (1 10)	5 (0.50)
ILI with RT-PCR–confirmed influenza A ^a	9 (0.92)	11 (1.12)	5 (0.50)

Relative risk reduction (95% CI) for		
VIR-2482 vs placebo ^b	-22.86 (-194.88, 48.81)	42.86 (-69.69, 80.76)

- 541 CDC, Centers for Disease Control and Prevention; EOIS, end of influenza season; ILI, influenza-like illness; RT-PCR, reverse
- transcriptase-polymerase chain reaction; WHO, World Health Organization.
- ^aParticipants with multiple occurrences of protocol-defined, CDC-defined, or WHO-defined illness with RT-PCR–confirmed
- 544 influenza A were counted once.
- ⁵⁴⁵ ^bThe 95% CIs are nominal, and not adjusted for multiplicity.
- 546

548 Supplementary Table 2. Symptoms Among Participants With Protocol-Defined ILI With

549 RT-PCR-Confirmed Influenza A Without Concomitant Coinfection Based on Flu-IIQ,

550 Overall and by Maximum Severity

	Placebo	VIR-2482 450 mg	VIR-2482 1200 mg
Symptoms, no. (%)	(n = 983)	(n = 981)	(n = 992)
Participants with any symptoms	25 (100)	23 (95.8)	21 (100)
Mild	0	1 (4.2)	2 (9.5)
Moderate	15 (60.0)	9 (37.5)	7 (33.3)
Severe	10 (40.0)	13 (54.2)	12 (57.1)
Cough	25 (100)	23 (95.8)	20 (95.2)
Mild	5 (20.0)	7 (29.2)	7 (33.3)
Moderate	16 (64.0)	10 (41.2)	10 (47.6)
Severe	4 (16.0)	6 (25.0)	3 (14.3)
Sore Throat	23 (92.0)	18 (75.0)	20 (95.2)
Mild	14 (56.0)	5 (20.8)	11 (52.4)
Moderate	7 (28.0)	9 (37.5)	7 (33.3)
Severe	2 (8.0)	4 (16.7)	2 (9.5)
Headache	21 (84.0)	19 (79.2)	21 (100)
Mild	5 (20.0)	9 (37.5)	5 (23.8)
Moderate	11 (44.0)	5 (20.8)	11 (52.4)
Severe	5 (20.0)	5 (20.8)	5 (23.8)
Nasal congestion	23 (92.0)	22 (91.7)	18 (85.7)
Mild	6 (24.0)	4 (16.7)	4 (19.1)
Moderate	13 (52.0)	14 (58.3)	9 (42.9)
Severe	4 (16.0)	4 (16.7)	5 (23.8)
Feeling feverish	21 (84.0)	18 (75.0)	18 (85.7)

Mild	5 (20.0)	7 (29.2)	6 (28.6)
Moderate	11 (44.0)	6 (25.0)	6 (28.6)
Severe	5 (20.0)	5 (20.8)	6 (28.6)
Body aches and pains	22 (88.0)	19 (79.2)	20 (95.2)
Mild	5 (20.0)	9 (37.5)	8 (38.1)
Moderate	11 (44.0)	4 (16.7)	6 (28.6)
Severe	6 (24.0)	6 (25.0)	6 (28.6)
Fatigue	25 (100)	22 (91.7)	19 (90.5)
Mild	8 (32.0)	7 (29.2)	3 (14.3)
Moderate	11 (44.0)	12 (50.0)	11 (52.4)
Severe	6 (24.0)	3 (12.5)	5 (23.8)
Neck pain	19 (76.0)	15 (62.5)	14 (66.7)
Mild	5 (20.0)	10 (41.7)	5 (23.8)
Moderate	11 (44.0)	3 (12.5)	7 (33.3)
Severe	3 (12.0)	2 (8.3)	2 (9.5)
Interrupted sleep	23 (92.0)	17 (70.8)	19 (90.5)
Mild	5 (20.0)	6 (25.0)	5 (23.8)
Moderate	10 (40.0)	5 (20.8)	8 (38.1)
Severe	8 (32.0)	6 (25.0)	6 (28.6)
Loss of appetite	23 (92.0)	18 (75.0)	18 (85.7)
Mild	11 (44.0)	9 (37.5)	9 (42.9)
Moderate	10 (40.0)	6 (25.0)	5 (23.8)
Severe	2 (8.0)	3 (12.5)	4 (19.1)

551 ILI, influenza-like illness; Flu-IIQ, Influenza Intensity and Impact Questionnaire; RT-PCR,

552 reverse transcriptase-polymerase chain reaction.

554 Supplementary Table 3. Solicited Injection-Site Reactions at 1 Hour Postdose (Safety Set)

	Placebo (n = 983)	VIR-2482 450 mg	VIR-2482 1200
	n (%)	(n = 981)	mg (n = 992)
		n (%)	n (%)
Any injection-site reaction	65 (6.6)	81 (8.3)	93 (9.4)
Grade 1	63 (6.4)	79 (8.1)	90 (9.1)
Grade 2	2 (0.2)	2 (0.2)	3 (0.3)
Pain	57 (5.8)	60 (6.1)	83 (8.4)
Grade 1	55 (5.6)	60 (6.1)	83 (8.4)
Grade 2	2 (0.2)	0	0
Swelling	9 (0.9)	24 (2.5)	25 (2.5)
Grade 1	9 (0.9)	24 (2.5)	24 (2.4)
Grade 2	0	0	1 (0.1)
Erythema	2 (0.2)	2 (0.2)	4 (0.4)
Grade 1	2 (0.2)	2 (0.2)	3 (0.3)
Grade 2	0	0	1 (0.1)
Bruising	2 (0.2)	8 (0.8)	3 (0.3)
Grade 1	2 (0.2)	8 (0.8)	2 (0.2)
Grade 2	0	0	1 (0.1)
Pruritis	4 (0.4)	6 (0.6)	6 (0.6)
Grade 1	4 (0.4)	4 (0.4)	6 (0.6)
Grade 2	0	2 (0.2)	0

- A participant with multiple reactions was counted only once for that reaction, and at the
- 556 maximum toxicity grade.

558 Supplementary Table 4. Local Injection-Site Reactions From the Study Intervention Diary

559 Card (Safety Set)

	Placebo (n = 983)	VIR-2482 450 mg	VIR-2482 1200
	n (%)	(n = 981)	mg (n = 992)
		n (%)	n (%)
Any injection-site reaction	272 (27.7)	292 (29.8)	293 (29.5)
Grade 1	227 (23.1)	3.1) 250 (25.5) 248 (25.0)	
Grade 2	38 (3.9)	35 (3.6)	39 (3.9)
Grade 3	7 (0.7)	7 (0.7)	6 (0.6)
Pain	260 (26.5)	279 (28.4)	277 (27.9)
Grade 1	222 (22.6)	240 (24.5)	237 (23.9)
Grade 2	31 (3.2)	32 (3.3)	34 (3.4)
Grade 3	7 (0.7)	7 (0.7)	6 (0.6)
Swelling	2 (0.2)	10 (1.0)	13 (1.3)
Grade 1	1 (0.1)	8 (0.8)	9 (0.9)
Grade 2	1 (0.1)	2 (0.2)	4 (0.4)
Erythema	5 (0.5)	7 (0.7)	10 (1.0)
Grade 1	4 (0.4)	6 (0.6)	10 (1.0)
Grade 2	1 (0.1)	1 (0.1)	0
Bruising	21 (2.1)	17 (1.7)	20 (2.0)
Grade 1	16 (1.6)	16 (1.6)	17 (1.7)
Grade 2	5 (0.5)	1 (0.1)	3 (0.3)

Induration	3 (0.3)	8 (0.8)	12 (1.2)
Grade 1	2 (0.2)	5 (0.5)	11 (1.1)
Grade 2	1 (0.1)	3 (0.3)	1 (0.1)

560 A participant with multiple reactions was counted only once for that reaction, and at the

562

⁵⁶¹ maximum toxicity grade.

564 Supplemental Table 5. Systemic Reactions From the Study Intervention Diary Card by

565 Symptom, Overall, and by Maximum Severity (Safety Set)

	Placebo	VIR-2482 450 mg	VIR-2482 1200 mg	
	(n = 983)	(n = 981)	(n = 992)	
	n (%)	n (%)	n (%)	
Any systemic reaction	268 (27.3)	265 (27.0)	283 (28.5)	
Mild	209 (21.3)	210 (21.4)	216 (21.8)	
Moderate	53 (5.4)	42 (4.3)	52 (5.2)	
Severe	6 (0.6)	13 (1.3)	15 (1.5)	
Potentially life-	0	0	0	
threatening				
Headache	175 (17.8)	160 (16.3)	168 (16.9)	
Mild	138 (14.0)	125 (12.7)	124 (12.5)	
Moderate	34 (3.5)	27 (2.8)	34 (3.4)	
Severe	3 (0.3)	8 (0.8)	10 (1.0)	
Myalgia	149 (15.2)	135 (13.8)	169 (17.0)	
Mild	130 (13.2)	121 (12.3)	148 (14.9)	
Moderate	17 (1.7)	13 (1.3)	17 (1.7)	
Severe	2 (0.2)	1 (0.1)	4 (0.4)	
Malaise	123 (12.5)	117 (11.9)	130 (13.1)	
Mild	101 (10.3)	96 (9.8)	98 (9.9)	
Moderate	20 (2.0)	18 (1.8)	28 (2.8)	

Severe	2 (0.2)	3 (0.3)	4 (0.4)
Shivering	43 (4.4)	44 (4.5)	60 (6.1)
Mild	38 (3.9)	33 (3.4)	43 (4.3)
Moderate	4 (0.4)	10 (1.0)	13 (1.3)
Severe	1 (0.1)	1 (0.1)	4 (0.4)
Fever ^a	13 (1.3)	11 (1.1)	11 (1.1)
Mild	7 (0.7)	6 (0.6)	8 (0.8)
Moderate	5 (0.5)	3 (0.3)	2 (0.2)
Severe	1 (0.1)	2 (0.2)	1 (0.1)
Potentially life-	0	0	0
threatening			

566 A participant with multiple reactions was counted only once for that reaction, and at the

567 maximum grade.

^aFever was graded using the Toxicity Grading Scale for Healthy Adult and Adolescent

569 Volunteers Enrolled in Preventative Vaccine Clinical Trials.

570 Supplementary Table 6. Influenza A Subtypes for Participants With Protocol-Defined ILI

571 With RT-PCR Confirmed Influenza A Without Concomitant Coinfection (Virology

572 Analysis Set)

	Placebo	VIR-2482	VIR-2482
	(n = 593)	450 mg	1200 mg
		(n = 579)	(n = 574)
No. (%) participants ^a	25 (4.2)	24 (4.2)	21 (3.7)
No. of protocol-defined ILI with RT-PCR-	25	25	21
confirmed influenza A (without coinfection),			
N1			
H1 pdm09, no. (%)	9 (36.0)	4 (16.0)	5 (23.8)
H3, no. (%)	14 (56.0)	18 (72.0)	12 (57.1)
Unknown, no. (%)	2 (8.0)	3 (12.0)	4 (19.1)

573 ILI, influenza-like illness; RT-PCR, reverse transcriptase-polymerase chain reaction.

^aIf a participant had multiple protocol-defined ILI with RT-PCR–confirmed influenza A without

575 coinfection, all (N1) were included in the summary. Percentages for influenza A subtypes are

576 based on N1.

577

579 Supplementary Table 7: Sequence and Phenotypic Data Availability for Participants With

580 **RT-PCR Confirmed Influenza A Virus (Safety Set)**

Study Population	Placebo	VIR-2482	VIR-2482	Total
		450 mg	1200 mg	
		n/N ^a	(%)	
Participants with HA	14/29 (48.3)	18/30 (60.0)	12/24 (50.0)	44/83 (53.0)
sequence data available				
Participants with phenotypic	15/29 (51.7)	17/30 (56.7)	10/24 (41.7)	42/83 (50.6)
data available				

- 581 RT-PCR, reverse transcriptase-polymerase chain reaction.
- ^an is number of participants with sequence or phenotypic data available; N is number of
- 583 participants with RT-PCR confirmed influenza A in the safety set.

PK parameter (unit) VIR-2482 450 mg VIR-2482 1200 mg Thigh Buttock Total Thigh Buttock Total C_{max} (µg/mL) 636 189 826 657 172 829 n Geometric mean 128 55.6 30.9 48.6 64.8 111 Geometric CV% 39.2 65.5 53.6 33.7 67.8 52.1 $C_{180} (\mu g/mL)$ 636 189 826 657 172 829 n 8.3 6.1 4.2 5.6 14 12.6 Geometric mean Geometric CV% 124.8 70.7 114.8 130.6 93.3 127.4 $A\overline{UC_{0-180}(d^*\mu g/mL)}$ 636 189 826 657 172 829 n Geometric mean 3960 2430 3540 9140 5030 8070 Geometric CV% 39.9 57.1 49.6 36.3 58.9 49.4 $AUC_{\infty}(d*\mu g/mL)$

584 Supplementary Table 8: Serum PK Parameters (PK Analysis Set)

n	240	82	322	253	71	324
Geometric mean	3970	2760	3620	9070	5830	8230
Geometric CV%	45.3	58.1	51.8	46.9	64.3	55.0
CL/F (mL/d)				1		
n	240	82	322	253	71	324
Geometric mean	113	163	124	132	206	146
Geometric CV%	45.3	58.1	51.8	46.9	64.3	55.0
V _z /F (L)				1		1
n	240	82	322	253	71	324
Geometric mean	7.9	12.8	9.0	9.2	15.7	10.3
Geometric CV%	34.7	55.6	46.6	30.1	61.0	45.0
T _{max} (d)		L	I		I	
n	636	189	826	657	172	829
Median	7.0	7.2	7.0	6.9	7.8	7.0
Min, max	2.8, 40.9	4.1, 35.8	2.8, 40.9	1.9, 57.9	4.9, 71.1	1.9, 71.1
T _{1/2} (d)	1	1	1	1	1	1

n	249	85	334	272	71	343
Median	55.1	56.7	55.4	54.5	55.7	54.7
Min, max	15.5, 76.7	26.1, 76.8	15.5, 76.8	14, 79	15.3, 77	14, 79

 $AUC\infty$, area under the concentration-time curve extrapolated from time zero to time infinity; AUC_{0-180} , partial area under the

586 concentration-time curve from time zero to day 180; CL/F, total body clearance following extravascular administration; C_{max},

587 maximum observed serum concentration; C₁₈₀, predicted serum concentration at day 180; CV, coefficient of variation; PK,

pharmacokinetics; T_{max} , time at which maximum serum concentration was observed; $T_{1/2}$, terminal elimination half-life; V_z/F , apparent

volume of distribution during the terminal elimination phase, following extravascular administration point.

			Days elapsed			
		Date of	from dose to	VIR-2482 serum	VIR-2482 NPS	
		protocol-	protocol-	concentration	concentration	Influenza A
Location	Date of dose	defined ILI	defined ILI	(µg/mL)	(µg/mL)	subtype
Buttock 450 mg	2022-11-01	2022-11-24	24	18.0	0.6	H3
	2022-11-07	2022-11-26	20	37.5	NC	H3
	2022-10-28	2022-11-03	7	18.9	NC	H1pdm09
Buttock 1200 mg	2022-11-04	2022-12-04	31	15.9	2.1	Н3
	2022-11-17	2022-11-30	14	_	NC	Unknown
Thigh 450 mg	2022-11-21	2022-12-19	29	32.4	NC	Н3
	2022-11-11	2022-12-01	21	46.1	NC	Unknown
	2022-11-21	2022-12-05	15	45.0	NC	Н3
	2022-11-02	2022-12-01	30	15.9	NC	H1pdm09
	2022-11-16	2022-11-28	13	70.4	_	Unknown
	2022-11-10	2022-11-21	12	65.1	NC	H3

591 Supplementary Table 9: PK and Virology Data From Protocol-Defined ILI Cases

	2022-11-08	2022-12-28	51	35.8	NC	H3
	2022-11-11	2022-11-23	13	37.8	NC	НЗ
	2022-11-28	2023-01-12	46	BQL	NC	H1pdm09
	2022-11-15	2022-12-13	29	47.0	NC	H3
	2022-10-28	2022-12-01	35	53.4	NC	НЗ
	2022-11-28	2023-02-13	78	34.6	NC	НЗ
	2022-11-28	2023-02-13	78	25.1	NC	H3
	2022-11-18	2022-11-21	4	74.6	2.8	H3
	2022-11-28	2022-12-12	15	80.8	NC	H3
	2022-10-26	2022-11-23	29	26.3	NC	Н3
	2022-11-09	2022-12-15	37	28.0	2.5	Н3
	2022-11-10	2022-11-24	15	46.7	1.0	Н3
	2022-11-08	2022-12-21	44	27.8	_	Unknown
	2022-11-16	2022-12-07	22	58.1	_	H1pdm09
	2022-11-16	2022-11-24	9	66.8	NC	H3
Thigh 1200 mg	2022-11-16	2022-11-19	4	205.6	NC	H3

2022-11-10	2022-11-13	4	102.5	0.7	H3
2022-11-17	2022-12-05	19	98.2	NC	Н3
2022-11-28	2022-12-27	30	69.7	2.4	НЗ
2022-12-01	2022-12-08	8	169.2	0.9	Н3
2022-12-01	2022-12-05	5	119.0	NC	НЗ
2022-11-28	2022-12-02	5	173.5	4.2	H1pdm09
2022-11-22	2022-12-10	19	170.4	NC	Н3
2022-11-07	2022-11-28	22	119.9	NC	Н3
2022-10-28	2022-11-10	14	122.0	_	Unknown
2022-10-19	2023-03-15	148	33.4	NC	H1pdm09
2022-12-05	2022-12-15	11	101.5	NC	H1pdm09
2022-11-07	2022-12-04	28	103.9	NC	H1pdm09
2022-12-05	2022-12-05	1	43.3	NC	Н3
2022-10-26	2022-12-12	48	57.8	_	Unknown
2022-11-22	2022-12-05	14	94.1	2.6	Н3
2022-11-15	2022-12-01	17	83.6	3.0	H1pdm09

2022-12-01	2022-12-28	28	116.9	_	Unknown
2022-12-02	2022-12-12	11	126.3	0.8	Н3

592 BQL, below the quantification limit; PK, pharmacokinetics; ILI, influenza-like illness; NC, not calculable; NPS, nasopharyngeal swab.

595 Supplementary Figure 1. Subgroup Analyses for the Occurrence of Protocol-Defined

596 Influenza-Like Illness With RT-PCR Confirmed Influenza A in Participants Receiving

597 VIR-2482 1200 mg

598



BMI, body mass index; NC, not calculable; RT-PCR, reverse transcriptase-polymerase chain reaction.

601 Supplementary Figure 2. VIR-2482 NPS:Serum Ratios by Dose and Timepoint (PK

602 Analysis Set)

603



EOIS, end of influenza season; NPS, nasopharyngeal swab; PK, pharmacokinetics.

The ratio of VIR-2482 in NPS samples versus serum is calculated as 100 x (VIR-2482 NPS

606 concentration/VIR-2482 serum concentration.